SEKISUI Diagnostics announced on Nov. 14, 2024 the completion of a £15.7 million (US$20.7 million) expansion of current good manufacturing practice (CGMP) capacity at the company’s UK site for its microbial contract development and manufacturing business, BioProduction by SEKISUI. The recent expansion includes new Grade C microbial fermentation and purification suites that will accommodate production scales up to 1000 L. Source: Biopharm International 19/11/2024